1
|
Buyssens L, Valenzuela A, Prims S, Ayuso M, Thymann T, Van Ginneken C, Van Cruchten S. Ontogeny of CYP3A and UGT activity in preterm piglets: a translational model for drug metabolism in preterm newborns. Front Pharmacol 2023; 14:1177541. [PMID: 37124224 PMCID: PMC10133700 DOI: 10.3389/fphar.2023.1177541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Accepted: 04/04/2023] [Indexed: 05/02/2023] Open
Abstract
Despite considerable progress in understanding drug metabolism in the human pediatric population, data remains scarce in preterm neonates. Improving our knowledge of the ADME properties in this vulnerable age group is of utmost importance to avoid suboptimal dosing, which may lead to adverse drug reactions. The juvenile (mini)pig is a representative model for hepatic drug metabolism in human neonates and infants, especially phase I reactions. However, the effect of prematurity on the onset of hepatic phase I and phase II enzyme activity has yet to be investigated in this animal model. Therefore, the aim of this study was to assess the ontogeny of CYP3A and UGT enzyme activity in the liver of preterm (gestational day 105-107) and term-born (gestational day 115-117) domestic piglets. In addition, the ontogeny pattern between the preterm and term group was compared to examine whether postconceptional or postnatal age affects the onset of enzyme activity. The following age groups were included: preterm postnatal day (PND) 0 (n = 10), PND 5 (n = 10), PND 11 (n = 8), PND 26 (n = 10) and term PND 0 (n = 10), PND 5 (n = 10), PND 11 (n = 8), PND 19 (n = 18) and PND 26 (n = 10). Liver microsomes were extracted, and the metabolism of CYP3A and UGT-specific substrates assessed enzyme activity. Preterm CYP3A activity was only detectable at PND 26, whereas term CYP3A activity showed a gradual postnatal increase from PND 11 onwards. UGT activity gradually increased between PND 0 and PND 26 in preterm and term-born piglets, albeit, being systematically lower in the preterm group. Thus, postconceptional age is suggested as the main driver affecting porcine CYP3A and UGT enzyme ontogeny. These data are a valuable step forward in the characterization of the preterm piglet as a translational model for hepatic drug metabolism in the preterm human neonate.
Collapse
Affiliation(s)
- Laura Buyssens
- Comparative Perinatal Development, Department of Veterinary Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Wilrijk, Belgium
| | - Allan Valenzuela
- Comparative Perinatal Development, Department of Veterinary Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Wilrijk, Belgium
| | - Sara Prims
- Comparative Perinatal Development, Department of Veterinary Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Wilrijk, Belgium
| | - Miriam Ayuso
- Comparative Perinatal Development, Department of Veterinary Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Wilrijk, Belgium
| | - Thomas Thymann
- Comparative Pediatrics and Nutrition, Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark
| | - Chris Van Ginneken
- Comparative Perinatal Development, Department of Veterinary Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Wilrijk, Belgium
| | - Steven Van Cruchten
- Comparative Perinatal Development, Department of Veterinary Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Wilrijk, Belgium
- *Correspondence: Steven Van Cruchten,
| |
Collapse
|
3
|
Stevens LJ, Zhu AZX, Chothe PP, Chowdhury SK, Donkers JM, Vaes WHJ, Knibbe CAJ, Alwayn IPJ, van de Steeg E. Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. Drug Metab Dispos 2021; 49:780-789. [PMID: 34330719 DOI: 10.1124/dmd.121.000521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Accepted: 06/23/2021] [Indexed: 11/22/2022] Open
Abstract
There is a lack of translational preclinical models that can predict hepatic handling of drugs. In this study, we aimed to evaluate the applicability of normothermic machine perfusion (NMP) of porcine livers as a novel ex vivo model to predict hepatic clearance, biliary excretion, and plasma exposure of drugs. For this evaluation, we dosed atorvastatin, pitavastatin, and rosuvastatin as model drugs to porcine livers and studied the effect of common drug-drug interactions (DDIs) on these processes. After 120 minutes of perfusion, 0.104 mg atorvastatin (n = 3), 0.140 mg pitavastatin (n = 5), or 1.4 mg rosuvastatin (n = 4) was administered to the portal vein, which was followed 120 minutes later by a second bolus of the statin coadministered with OATP perpetrator drug rifampicin (67.7 mg). After the first dose, all statins were rapidly cleared from the circulation (hepatic extraction ratio > 0.7) and excreted into the bile. Presence of human-specific atorvastatin metabolites confirmed the metabolic capacity of porcine livers. The predicted biliary clearance of rosuvastatin was found to be closer to the observed biliary clearance. A rank order of the DDI between the various systems upon coadministration with rifampicin could be observed: atorvastatin (AUC ratio 7.2) > rosuvastatin (AUC ratio 3.1) > pitavastatin (AUC ratio 2.6), which is in good agreement with the clinical DDI data. The results from this study demonstrated the applicability of using NMP of porcine livers as a novel preclinical model to study OATP-mediated DDI and its effect on hepatic clearance, biliary excretion, and plasma profile of drugs. SIGNIFICANCE STATEMENT: This study evaluated the use of normothermic machine perfusion (NMP) of porcine livers as a novel preclinical model to study hepatic clearance, biliary excretion, plasma (metabolite) profile of statins, and OATP-mediated DDI. Results showed that NMP of porcine livers is a reliable model to study OATP-mediated DDI. Overall, the rank order of DDI severity indicated in these experiments is in good agreement with clinical data, indicating the potential importance of this new ex vivo model in early drug discovery.
Collapse
Affiliation(s)
- L J Stevens
- Department of Surgery, Leiden University Medical Centre (LUMC) Transplant Center, Leiden, The Netherlands (L.J.S., I.P.J.A.); The Netherlands Organization for Applied Scientific Research (TNO), Zeist, The Netherlands (L.J.S., J.M.D., W.H.J.V., E.v.d.S.); Quantitative Solutions (A.Z.X.Z.), Department of Drug Metabolism & Pharmacokinetic (P.P.C., S.K.C.), Takeda Pharmaceutical International, Cambridge, Massachusetts; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden, The Netherlands (C.A.J.K.); and Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein and Utrecht, The Netherlands (C.A.J.K.)
| | - A Z X Zhu
- Department of Surgery, Leiden University Medical Centre (LUMC) Transplant Center, Leiden, The Netherlands (L.J.S., I.P.J.A.); The Netherlands Organization for Applied Scientific Research (TNO), Zeist, The Netherlands (L.J.S., J.M.D., W.H.J.V., E.v.d.S.); Quantitative Solutions (A.Z.X.Z.), Department of Drug Metabolism & Pharmacokinetic (P.P.C., S.K.C.), Takeda Pharmaceutical International, Cambridge, Massachusetts; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden, The Netherlands (C.A.J.K.); and Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein and Utrecht, The Netherlands (C.A.J.K.)
| | - P P Chothe
- Department of Surgery, Leiden University Medical Centre (LUMC) Transplant Center, Leiden, The Netherlands (L.J.S., I.P.J.A.); The Netherlands Organization for Applied Scientific Research (TNO), Zeist, The Netherlands (L.J.S., J.M.D., W.H.J.V., E.v.d.S.); Quantitative Solutions (A.Z.X.Z.), Department of Drug Metabolism & Pharmacokinetic (P.P.C., S.K.C.), Takeda Pharmaceutical International, Cambridge, Massachusetts; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden, The Netherlands (C.A.J.K.); and Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein and Utrecht, The Netherlands (C.A.J.K.)
| | - S K Chowdhury
- Department of Surgery, Leiden University Medical Centre (LUMC) Transplant Center, Leiden, The Netherlands (L.J.S., I.P.J.A.); The Netherlands Organization for Applied Scientific Research (TNO), Zeist, The Netherlands (L.J.S., J.M.D., W.H.J.V., E.v.d.S.); Quantitative Solutions (A.Z.X.Z.), Department of Drug Metabolism & Pharmacokinetic (P.P.C., S.K.C.), Takeda Pharmaceutical International, Cambridge, Massachusetts; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden, The Netherlands (C.A.J.K.); and Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein and Utrecht, The Netherlands (C.A.J.K.)
| | - J M Donkers
- Department of Surgery, Leiden University Medical Centre (LUMC) Transplant Center, Leiden, The Netherlands (L.J.S., I.P.J.A.); The Netherlands Organization for Applied Scientific Research (TNO), Zeist, The Netherlands (L.J.S., J.M.D., W.H.J.V., E.v.d.S.); Quantitative Solutions (A.Z.X.Z.), Department of Drug Metabolism & Pharmacokinetic (P.P.C., S.K.C.), Takeda Pharmaceutical International, Cambridge, Massachusetts; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden, The Netherlands (C.A.J.K.); and Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein and Utrecht, The Netherlands (C.A.J.K.)
| | - W H J Vaes
- Department of Surgery, Leiden University Medical Centre (LUMC) Transplant Center, Leiden, The Netherlands (L.J.S., I.P.J.A.); The Netherlands Organization for Applied Scientific Research (TNO), Zeist, The Netherlands (L.J.S., J.M.D., W.H.J.V., E.v.d.S.); Quantitative Solutions (A.Z.X.Z.), Department of Drug Metabolism & Pharmacokinetic (P.P.C., S.K.C.), Takeda Pharmaceutical International, Cambridge, Massachusetts; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden, The Netherlands (C.A.J.K.); and Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein and Utrecht, The Netherlands (C.A.J.K.)
| | - C A J Knibbe
- Department of Surgery, Leiden University Medical Centre (LUMC) Transplant Center, Leiden, The Netherlands (L.J.S., I.P.J.A.); The Netherlands Organization for Applied Scientific Research (TNO), Zeist, The Netherlands (L.J.S., J.M.D., W.H.J.V., E.v.d.S.); Quantitative Solutions (A.Z.X.Z.), Department of Drug Metabolism & Pharmacokinetic (P.P.C., S.K.C.), Takeda Pharmaceutical International, Cambridge, Massachusetts; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden, The Netherlands (C.A.J.K.); and Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein and Utrecht, The Netherlands (C.A.J.K.)
| | - I P J Alwayn
- Department of Surgery, Leiden University Medical Centre (LUMC) Transplant Center, Leiden, The Netherlands (L.J.S., I.P.J.A.); The Netherlands Organization for Applied Scientific Research (TNO), Zeist, The Netherlands (L.J.S., J.M.D., W.H.J.V., E.v.d.S.); Quantitative Solutions (A.Z.X.Z.), Department of Drug Metabolism & Pharmacokinetic (P.P.C., S.K.C.), Takeda Pharmaceutical International, Cambridge, Massachusetts; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden, The Netherlands (C.A.J.K.); and Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein and Utrecht, The Netherlands (C.A.J.K.)
| | - E van de Steeg
- Department of Surgery, Leiden University Medical Centre (LUMC) Transplant Center, Leiden, The Netherlands (L.J.S., I.P.J.A.); The Netherlands Organization for Applied Scientific Research (TNO), Zeist, The Netherlands (L.J.S., J.M.D., W.H.J.V., E.v.d.S.); Quantitative Solutions (A.Z.X.Z.), Department of Drug Metabolism & Pharmacokinetic (P.P.C., S.K.C.), Takeda Pharmaceutical International, Cambridge, Massachusetts; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden, The Netherlands (C.A.J.K.); and Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein and Utrecht, The Netherlands (C.A.J.K.)
| |
Collapse
|